Building a Pharmacological Treatment of Bronchial Asthma Presentation
You need to create a clinical presentation on pharmacological treatment for bronchial asthma. This is something I've done dozens of times for hospital grand rounds, pharmacist education sessions, and medical student lectures. The core difficulty isn't the content — it's organizing a disease that has multiple tiers of severity, several drug classes, and a constantly updating guideline framework into something coherent in under twenty slides. A solid deck starts with the GINA guideline framework as its backbone. Every slide should tie back to the stepwise approach — steps one through five — because that is the structure clinicians actually use at the bedside. Don't scatter drug information randomly. Put it where the step belongs. The first few slides should cover pathophysiology briefly. Inflammatory mediators, airway hyperresponsiveness, smooth muscle constriction. You are not teaching a basic science course here, so three or four slides max. Then move immediately to the classification of asthma severity: intermittent, mild persistent, moderate persistent, severe persistent. The old NIH classification still appears on board exams, but clinicians in practice follow GINA now. I usually include a side-by-side comparison slide noting that distinction because it saves questions later.
From there the pharmacological content splits into two buckets: relievers and controllers. That is the fundamental conceptual split everyone needs to understand, and it should be visually obvious in your deck.
Reliever Medications
Short-acting beta-agonists remain the first-line rescue therapy. Albuterol (salbutamol) 90 micrograms per actuation, two puffs via MDI with a spacer as needed. This is step one for intermittent asthma. The mechanism is straightforward — beta-2 receptor agonism causes bronchodilation within minutes, lasting four to six hours. Here is a point most presenters skip: SABA overuse is a real clinical problem. When a patient is using their albuterol inhaler more than twice a week for symptom relief, that is not normal. It indicates uncontrolled asthma. I once had a case where a patient was using nearly an entire canister per month and we missed it because nobody asked about refill frequency. The workaround is simple — add a question about inhaler usage to every asthma follow-up, not just symptom scoring. Ipratropium bromide is the anticholinergic alternative. It works slower, peaks around two hours, and is more useful in acute severe exacerbations when combined with albuterol in the emergency setting. Not first-line for routine management.
Get the Full Details
Controller Medications by Step
Step two: low-dose inhaled corticosteroid (ICS). Fluticasone, budesonide, beclomethasone. The anti-inflammatory effect reduces airway edema, mucus production, and hyperresponsiveness over weeks. This is where most treatment failures happen because patients stop using the ICS once they feel better. The inhaler is not a rescue device. It is a maintenance device. I always make sure my slides explicitly state that distinction with a bold callout box. Step three adds a long-acting beta-agonist (LABA) to the ICS. Formoterol and salmeterol are the standard options. Formoterol has a faster onset — about one minute compared to salmeterol's five to ten minutes — which matters if you are discussing dual maintenance and reliever therapy (MART). The GINA guideline shift toward preferring ICS-formoterol as both maintenance and reliever is significant. It reduces exacerbation rates compared to SABA reliever plus ICS-LABA maintenance. This should be a dedicated slide with the supporting trial data. Step four is medium-dose ICS-LABA. Step five introduces worst-case scenario options: high-dose ICS-LABA plus tiotropium, leukotriene receptor antagonist, or biologic therapy. The biologics section — omalizumab, mepolizumab, benralizumab, dupilumab — deserves careful handling. These are not for general asthma. They target specific phenotypes: allergic (anti-IgE), eosinophilic (anti-IL-5/IL-5R), or type 2 inflammation (anti-IL-4/IL-13). Prescribing them without phenotype characterization is a waste of resources and exposes patients to cost and risk without benefit.
Practical Pitfalls I Have Seen
The most common error in these presentations is listing drugs without addressing delivery devices. An ICS is useless if the patient does not know how to use an MDI correctly. Spacer devices improve lung deposition from approximately ten percent to thirty-five percent with MDIs. That is a threefold difference. Include a practical demonstration slide showing proper technique. I film myself doing it with a cheap training inhaler and embed the video in the deck. The audience stays engaged and you answer the technique question before it comes up. Another frequent gap: steroid inhaler side effects. Oral thrush and dysphonia occur in a meaningful percentage of patients. Rinsing the mouth after each use reduces thrush risk substantially. These are small points but they come up constantly in practice. Acknowledge the limitations. ICS-LABA combinations carry a black box warning for asthma-related death, though the absolute risk is extremely low when used appropriately. Tiotropium adds a glaucoma warning. Biologics require specialized infusion setup and monitoring. Being honest about these trade-offs makes the presentation more credible than one that presents the treatment algorithm as risk-free.
Structuring the Deck
Twenty-five to thirty slides is the typical range for a clinical education session. Slide one is title and objectives. Slides two through four: epidemiology and pathophysiology overview. Slides five through seven: severity classification. Slides eight through twenty: pharmacotherapy organized by GINA step. Slides twenty-one through twenty-four: special populations — pregnancy, children, elderly. Slide twenty-five: follow-up and monitoring parameters. Slide twenty-six: references. Use tables wherever possible. A table comparing all available ICS doses with their equivalent potency makes quick reference easier than prose. A table mapping LABA options to onset time and duration is similarly useful. Slide design should prioritize scannability. Nobody reads paragraphs off a presentation. Short bullet points, clear labels, one concept per slide. Include the exact topic "Tratamiento Farmacologico De Asma Bronquial Ppt" somewhere in your title or subtitle if you need it to match a search query. It does not need to appear more than once. The content itself is what matters.
Creating the File
If you are building this from scratch, start with a clinical template rather than a blank slide. Most hospital systems have branded templates with appropriate branding and accessibility settings. If you are working independently, Google Slides or PowerPoint will both handle the content fine. Export as PDF for distribution so formatting does not break on different systems. I keep a master deck with updated GINA step references and swap out the drug names and dosages as guidelines change. The 2024 and 2025 updates shifted some recommendations around MART therapy, so verifying your source year is important before presenting to a clinical audience. Presenting outdated step recommendations will get you corrected within five minutes. There is no single official download link for a complete pharmacological treatment presentation because these are typically institution-specific. You will need to build your own or adapt an existing educational resource. Major respiratory societies like GINA, ATS, and ERS publish guidelines that you can reference directly. Their materials are freely available and carry more authority than any random downloadable deck you might find online.
The work here is straightforward if you respect the guideline structure and acknowledge where the evidence ends and clinical judgment begins. Asthma management is not a one-size problem. Your presentation should reflect that nuance rather than presenting a simplified algorithm that breaks down at the edge cases.
